[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypofractionated-dose\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypofractionated-dose":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100601877","clinical-research-on-moderately-hypofractionated-adaptive-postoperative-radiotherapy-for-high-risk-endometrial-cancer-100601877",false,"NCT07116213","Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age : 18-70 years old.\n* Performance Status :\n\nECOG score 0-2.\n\n* Expected to comply with oART (Online Adaptive Radiotherapy) workflow.\n* Initial Surgical Treatment :\n\nTotal hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and\u002For para-aortic lymph node dissection\u002Fsampling or sentinel lymph node biopsy.\n\n* Pathological Staging \\& Histology (per FIGO 2009):\n\nStage I :\n\nGrade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion).\n\nGrade 2 endometrioid adenocarcinoma with deep myometrial invasion and extensive LVSI.\n\nGrade 3 endometrioid adenocarcinoma with deep myometrial invasion. Stage II-IIIC1 : Endometrioid carcinoma. Stage I-IIIC1 : Serous carcinoma or clear cell carcinoma.\n\n* Informed Consent :\n* Patients and families fully understand the study protocol.\n* Voluntarily participate and sign informed consent forms before enrollment\n\nExclusion Criteria:\n\n* Prior Radiotherapy : History of abdominal or pelvic irradiation.\n* Treatment Interval :\n\nWithout adjuvant chemotherapy: \\>12 weeks between surgery and radiotherapy initiation.\n\nWith adjuvant chemotherapy: \\>6 months between surgery and radiotherapy initiation.\n\n* Malignancy History : Prior diagnosis of other malignancies.\n* Pregnancy\u002FLactation : Pregnant or breastfeeding women.\n* Active Infection : Fever or uncontrolled active infection.\n* Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status).\n* Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders","FEMALE","18 Years","70 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","1. Study Type: Single-center, single-arm, prospective study.\n2. Sample Size: 20 patients with high-risk endometrial cancer were enrolled.\n3. Treatment Procedure:\n\n   The existing clinical oART (Online Adaptive Radiotherapy) workflow protocol for malignant tumors used in our department was applied.\n\n   Procedures included simulation, target volume delineation, radiotherapy planning, and treatment delivery.\n\n   External beam radiation therapy (EBRT) was delivered using moderate hypofractionation.\n\n   If indicated, brachytherapy was performed after the completion of EBRT. When combined with chemotherapy, radiotherapy could be administered during chemotherapy intervals or after completion of chemotherapy.\n4. Study Endpoints:\n\nPrimary Endpoint: Incidence of acute toxicity. Secondary Endpoints: 3-year failure-free survival (FFS) rate, incidence of chronic toxicity, quality of life (QoL), treatment costs, etc.",[26,27,28,29,30],"Endometrial Cancer","Hypofractionated Dose","Radiotherapy, Adjuvant","Side Effects","Survival , Tumor",[32,33,34],"endometrial cancer","Hypofractionated dose","Radiotherapy","RECRUITING","2025-08-04",{"date":38,"type":39},"2025-08-11","ACTUAL",{"date":41,"type":39},"2025-06-30",{"date":43,"type":20},"2030-12-30",{"name":45,"class":46},"Xiaorong Hou","OTHER"]